Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.74 |
| ▸ | TK1 | P04183 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265601 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL27444298 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL265600 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL31289437 | 1.00 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL15187886 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL15498284 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL12932156 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL15498298 | 0.91 | RNASE1 (0.63) | RNASE1TK1 | |
| SCHEMBL8659547 | 0.90 | RNASE1 (0.62) | RNASE1TK1 | |
| SCHEMBL8659542 | 0.90 | RNASE1 (0.62) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8889851-B2 | Methods for the synthesis and purification of oligomers | AGILENT TECHNOLOGIES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8629265-B2 | Method for producing phosphate-bridged nucleoside conjugates | UNIVERSITAET HAMBURG (DE) | 2014-01-14 | — | — | US | disclosed |
| EP-2599785-A1 | Novel methods for the synthesis and purification of oligomers | Agilent Technologies, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137861-A1 | NOVEL METHODS FOR THE SYNTHESIS AND PURIFICATION OF OLIGOMERS | AGILENT TECHNOLOGIES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2007110624-A2 | IMMOBILISED REAGENT | UNIVERSITY COURT OF THE UNIVERSITY OFEDINBURGH (GB) | 2007-10-04 | — | — | WO | disclosed |
| US-7145000-B2 | Markable compounds for easy synthesis of 3'-[18F] fluoro-3'-deoxynucleotides, and method for their production | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20050143338-A1 | 1-(2,5'-Anhydro-lyxofuranosyl) thymines for the synthesis of radiomarked fluoro-3 deoxynucleotides | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-06-30 | — | — | US | disclosed |
| EP-1419167-B1 | 1-(2,5'-ANHYDRO-LYXOFURANOSYL) THYMINES FOR THE SYNTHESIS OF RADIOMARKED FLUORO-3' DEOXYNUCLEOTIDES | DEUTSCHES KREBSFORSCH (DE) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | RNASE1 126/4885TK1 223/4885LMNA 4253/4885 |
| US-20050143338-A1 | 1-(2,5'-Anhydro-lyxofuranosyl) thymines for the synthesis of radiomarked fluoro-3 deoxynucleotides | NT5C3B, OGG1, XRN2 | RNASE1 95/4885TK1 53/4885LMNA 291/4885 |
| US-20190048344-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | RNASE1 126/4885TK1 223/4885LMNA 4253/4885 |
| US-20130137861-A1 | NOVEL METHODS FOR THE SYNTHESIS AND PURIFICATION OF OLIGOMERS | RTCB, CACYBP, PHAX | RNASE1 657/4885TK1 245/4885LMNA 133/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | RNASE1 126/4885TK1 223/4885LMNA 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.